Furthermore, given the positive correlation between ER and HER2 expression in HER2 non-overexpressing BCs [229], the potential clinical benefit of combination therapy using anti-HER2 drugs and anti-hormone drugs warrants investigation in BC patients lacking HER2 overexpression in future studies. Here, ERBB2 is linked to breast cancer.